热门资讯> 正文

展望眼用贝伐单抗治疗干性AMD获得批准

2026-07-25 03:20

The US FDA has approved Outlook Therapeutics' (OTLK) Lytenava (bevacizumab-vikg) for wet AMD.
Lytevana is the first ophthalmic bevacizumab approved for the condition. It is expected to launch by the end of the year.
The standard formulation of bevacizumab is marketed by Roche (RHHBY) as Avastin.
The drug is administered once a month.

More on Outlook Therapeutics

Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
Outlook gains as wet AMD therapy reconsidered for FDA review
Outlook Therapeutics prices $5M registered direct offering
Seeking Alpha’s Quant Rating on Outlook Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。